The subdued stock price reaction suggests that Gilead Sciences, Inc.'s (NASDAQ:GILD) strong earnings didn't offer any surprises. We think that investors have missed some encouraging factors ...

FOSTER CITY, Calif., April 29, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA ...

Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. Gilead Sciences beat analysts’ revenue ...

Gilead Sciences fell 2.52% in premarket trading on the news. The company makes medication for treating HIV and AIDS. Other biopharma firms also fell. The move: Gilead Sciences dropped 2.52% in ...

Gilead Sciences recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio ...

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was ...

The results come after Salesforce recently announced former Gilead Sciences (GILD) CFO Robin Washington will join the company on March 21 as chief operating and financial officer. Shares of ...